Compare CTRE & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRE | KRYS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 7.8B |
| IPO Year | 2013 | 2017 |
| Metric | CTRE | KRYS |
|---|---|---|
| Price | $38.19 | $276.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $42.40 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 1.9M | 225.0K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | 96.25 | ★ 128.00 |
| EPS | 1.57 | ★ 6.84 |
| Revenue | ★ $476,393,000.00 | $389,130,000.00 |
| Revenue This Year | $5.97 | $38.74 |
| Revenue Next Year | $13.39 | $32.53 |
| P/E Ratio | ★ $23.62 | $40.09 |
| Revenue Growth | ★ 60.79 | 33.94 |
| 52 Week Low | $27.27 | $123.03 |
| 52 Week High | $41.72 | $298.30 |
| Indicator | CTRE | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 59.92 |
| Support Level | $35.57 | $254.53 |
| Resistance Level | $38.27 | $297.14 |
| Average True Range (ATR) | 0.92 | 7.54 |
| MACD | -0.05 | 1.65 |
| Stochastic Oscillator | 42.77 | 86.30 |
CareTrust REIT Inc is a self-administered, publicly traded REIT engaged in the ownership, acquisition, financing, development, and leasing of skilled nursing, seniors housing, and other healthcare-related properties. The company has one reportable segment consisting of investments in healthcare-related real estate assets. It generates revenues by leasing healthcare-related properties to healthcare operators under triple-net lease arrangements, in which the tenant is solely responsible for property-related costs. The company operates in Domestic and Foreign markets, with the majority of revenue coming from Domestic operations.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.